CIAM
BCRX icon

Caitong International Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Caitong International Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.32K Buy
+139
New +$1.08K ﹤0.01% 1348
2025
Q3 		– Sell
-1,092
Closed -$9.78K – 1962
2025
Q2 		$9.78K Buy
1,092
+1,082
+10,820% +$10.1K 0.01% 734
2025
Q1 		$75 Buy
+10
New +$81 ﹤0.01% 2004

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Caitong International Asset Management's BCRX Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in BioCryst Pharmaceuticals (BCRX) in Q1 2026: 139 shares worth $1.32K. The stake represents ﹤0.01% of the portfolio and ranks #1348 among its holdings. This is a return to the name: Caitong International Asset Management previously reported a position in BCRX as recently as Q2 2025.

Caitong International Asset Management first reported a position in BCRX in Q1 2025 and has held it in 3 quarters since. The position peaked at $9.78K in Q2 2025. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Caitong International Asset Management held 139 shares of BioCryst Pharmaceuticals worth $1.32K as of Q1 2026.
  • BioCryst Pharmaceuticals was a new Caitong International Asset Management position in Q1 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #1348 holding.
  • Caitong International Asset Management first reported a position in BioCryst Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • Caitong International Asset Management's BioCryst Pharmaceuticals position peaked at $9.78K in Q2 2025.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.